Agonist activation and alpha-bungarotoxin inhibition of wild type and mutant alpha7 nicotinic acetylcholine receptors.
The properties of wild type and mutant rat nicotinic alpha7 receptors expressed in Xenopus oocytes were investigated using electrophysiology and site-directed mutagenesis. When compared at individual agonist concentrations, neither the normalised nicotinic, nor acetylcholine, responses of the wild type receptors were significantly different from the corresponding responses obtained from a first extracellular domain mutant, phenylalanine(189)tyrosine (P0.05). The dissociation constants (K(D)) of the wild type (4.7 nM) and Phe(189)Tyr mutant (5.2 nM) receptors for alpha-bungarotoxin were estimated by an electrophysiological approach. The similarity of the results suggests that the mutation did not lead to a widespread disruption of structure-function relationships, although a slight change in nicotine sensitivity may have occurred. In contrast, the mutations (Tyr(190)Gln, first extracellular domain), (Glu(261)Ala, M2 region) severely compromised receptor function. An additional mutation was made in a negatively charged motif of the second extracellular domain which is conserved in homomeric nicotinic receptors. This mutation, Asp(268)Ala, also caused a loss of function. Thus the structure-function relationships in nicotinic alpha7 receptors have parallels with heteromeric nicotinic receptors, but there may also be some marked differences.
Kempsill
F E
FE
Department of Physiology and Pharmacology, University of Strathclyde, Strathclyde Institute for Biomedical Sciences, 27 Taylor Street, Glasgow, UK.
Covernton
P J
PJ
Whiting
P J
PJ
Connolly
J G
JG
D000109:Acetylcholine / Q000494:pharmacology; D000200:Action Potentials / Q000187:drug effects*; D000818:Animals; D002038:Bungarotoxins / Q000494:pharmacology*; D016297:Mutagenesis, Site-Directed; D009538:Nicotine / Q000494:pharmacology; D018722:Nicotinic Agonists / Q000494:pharmacology; D010649:Phenylalanine / Q000235:genetics*; D051381:Rats; D011978:Receptors, Nicotinic / Q000737:chemistry / Q000187:drug effects* / Q000235:genetics; D013329:Structure-Activity Relationship; D014443:Tyrosine / Q000235:genetics*; D014665:Vasodilator Agents / Q000494:pharmacology; D014981:Xenopus; D064569:alpha7 Nicotinic Acetylcholine Receptor
D002038:Bungarotoxins; C579165:Chrna7 protein, rat; D018722:Nicotinic Agonists; D011978:Receptors, Nicotinic; D014665:Vasodilator Agents; D064569:alpha7 Nicotinic Acetylcholine Receptor; D014443:Tyrosine; D010649:Phenylalanine; D009538:Nicotine; D000109:Acetylcholine